Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 4
1998 1
1999 3
2000 6
2001 4
2002 3
2003 1
2004 1
2006 2
2010 3
2011 3
2012 1
2013 3
2015 1
2016 2
2017 1
2018 1
2019 2
2020 3
2021 2
2022 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Yap TA, et al. Among authors: fretland aj. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. Nat Med. 2023. PMID: 37277454 Free PMC article. Clinical Trial.
Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib.
Papp R, Trimble L, Fretland AJ, Manohar R, Phipps R, Kvaerno L, Perryman AL, Reynolds G, Black WC. Papp R, et al. Among authors: fretland aj. Drug Metab Dispos. 2024 Feb 20:DMD-AR-2023-001611. doi: 10.1124/dmd.123.001611. Online ahead of print. Drug Metab Dispos. 2024. PMID: 38378703 Free article.
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.
Vasalou C, Ferguson D, Li W, Muse V, Gibbons FD, Sonzini S, Zhang G, Pop-Damkov P, Gangl E, Balachander SB, Wen S, Schuller AG, Puri S, Mazza M, Ashford M, Fretland AJ, McGinnity DF, Jones RDO. Vasalou C, et al. Among authors: fretland aj. Mol Pharm. 2022 Jan 3;19(1):172-187. doi: 10.1021/acs.molpharmaceut.1c00715. Epub 2021 Dec 10. Mol Pharm. 2022. PMID: 34890209
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
Pilla Reddy V, Fretland AJ, Zhou D, Sharma S, Chen B, Vishwanathan K, McGinnity DF, Xu Y, Ware JA. Pilla Reddy V, et al. Among authors: fretland aj. Cancer Chemother Pharmacol. 2021 Sep;88(3):451-464. doi: 10.1007/s00280-021-04302-5. Epub 2021 Jun 2. Cancer Chemother Pharmacol. 2021. PMID: 34080039 Free PMC article.
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991.
Goliaei A, Woods HA, Tron AE, Belmonte MA, Secrist JP, Ferguson D, Drew L, Fretland AJ, Aldridge BB, Gibbons FD. Goliaei A, et al. Among authors: fretland aj. CPT Pharmacometrics Syst Pharmacol. 2020 Oct;9(10):561-570. doi: 10.1002/psp4.12552. Epub 2020 Sep 17. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32860732 Free PMC article.
49 results